UNSPSC 51161721: Sivelestat

This classification denotes a protease inhibitor with the molecular formula C20H22N2O7S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier DWI62G0P59, chemically known as o-(p-hydroxybenzenesulfonamido)hippuric acid, pivalate (ester) but generally known as sivelestat, which bears US NIH Compound Identifier 107706. European Medicines Agency schedules Sivelestat in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10543MIG.

UNSPSC 51161721 Sivelestat, a Commodity code, shows limited recent state and local procurement activity tied directly to its nominal pharmaceutical scope. The two recent opportunities posted under this code diverge significantly from sivelestat specifically: Seminole County, Florida is procuring naloxone and drug deactivation systems through an IFB, while Hall County, Georgia is seeking an on-site pharmacy services provider through an RFQ/P. Neither solicitation targets sivelestat as a line item or mentions the drug by name. State and local issuing bodies using this code include county-level health and human services departments and county employee benefits offices. The scope of work actually being solicited spans emergency response pharmaceuticals (naloxone), pharmacy operational services, and health plan administration support rather than sivelestat procurement specifically.

Seminole County, Florida and Hall County, Georgia represent the only recent identified activity. Seminole County's IFB, posted June 30, 2026 with a July 26, 2023 response date, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term plus one-year renewal option. Hall County's RFQ/P #47-010, posted May 4, 2026 with a June 4, 2026 response deadline, seeks a single vendor to provide on-site pharmacy services at the county's family health center clinic, with an initial January 1, 2027 start date and four additional one-year renewal options. Neither opportunity specifies set-aside designations. The code does not show active sivelestat-specific demand in recent state and local procurement; the mismatch between code assignment and actual solicitation scope suggests limited relevance for vendors focused on that pharmaceutical specifically.